Cargando…
Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2
Predicting disease severity in patients infected with SARS-CoV-2 is difficult. Soluble angiotensin-converting enzyme 2 (sACE2) arises from the shedding of membrane ACE2 (mACE2), which is a receptor for SARS-CoV-2 spike protein. We evaluated the predictive value of sACE2 compared with known biomarker...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031748/ https://www.ncbi.nlm.nih.gov/pubmed/35453934 http://dx.doi.org/10.3390/diagnostics12040886 |
_version_ | 1784692468083589120 |
---|---|
author | Díaz-Troyano, Noelia Gabriel-Medina, Pablo Weber, Stephen Klammer, Martin Barquín-DelPino, Raquel Castillo-Ribelles, Laura Esteban, Angels Hernández-González, Manuel Ferrer-Costa, Roser Pumarola, Tomas Rodríguez-Frías, Francisco |
author_facet | Díaz-Troyano, Noelia Gabriel-Medina, Pablo Weber, Stephen Klammer, Martin Barquín-DelPino, Raquel Castillo-Ribelles, Laura Esteban, Angels Hernández-González, Manuel Ferrer-Costa, Roser Pumarola, Tomas Rodríguez-Frías, Francisco |
author_sort | Díaz-Troyano, Noelia |
collection | PubMed |
description | Predicting disease severity in patients infected with SARS-CoV-2 is difficult. Soluble angiotensin-converting enzyme 2 (sACE2) arises from the shedding of membrane ACE2 (mACE2), which is a receptor for SARS-CoV-2 spike protein. We evaluated the predictive value of sACE2 compared with known biomarkers of inflammation and tissue damage (CRP, GDF-15, IL-6, and sFlt-1) in 850 patients with and without SARS-CoV-2 with different clinical outcomes. For univariate analyses, median differences between biomarker levels were calculated for the following patient groups (classified by clinical outcome): RT-PCR-confirmed SARS-CoV-2 positive (Groups 1–4); RT-PCR-confirmed SARS-CoV-2 negative following previous SARS-CoV-2 infection (Groups 5 and 6); and ‘SARS-CoV-2 unexposed’ patients (Group 7). Median levels of CRP, GDF-15, IL-6, and sFlt-1 were significantly higher in hospitalized patients with SARS-CoV-2 compared with discharged patients (all p < 0.001), whereas levels of sACE2 were significantly lower (p < 0.001). ROC curve analysis of sACE2 provided cut-offs for predicting hospital admission (≤0.05 ng/mL (positive predictive value: 89.1%) and ≥0.42 ng/mL (negative predictive value: 84.0%)). These findings support further investigation of sACE2, as a single biomarker or as part of a panel, to predict hospitalization risk and disease severity in patients with SARS-CoV-2 infection. |
format | Online Article Text |
id | pubmed-9031748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90317482022-04-23 Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2 Díaz-Troyano, Noelia Gabriel-Medina, Pablo Weber, Stephen Klammer, Martin Barquín-DelPino, Raquel Castillo-Ribelles, Laura Esteban, Angels Hernández-González, Manuel Ferrer-Costa, Roser Pumarola, Tomas Rodríguez-Frías, Francisco Diagnostics (Basel) Article Predicting disease severity in patients infected with SARS-CoV-2 is difficult. Soluble angiotensin-converting enzyme 2 (sACE2) arises from the shedding of membrane ACE2 (mACE2), which is a receptor for SARS-CoV-2 spike protein. We evaluated the predictive value of sACE2 compared with known biomarkers of inflammation and tissue damage (CRP, GDF-15, IL-6, and sFlt-1) in 850 patients with and without SARS-CoV-2 with different clinical outcomes. For univariate analyses, median differences between biomarker levels were calculated for the following patient groups (classified by clinical outcome): RT-PCR-confirmed SARS-CoV-2 positive (Groups 1–4); RT-PCR-confirmed SARS-CoV-2 negative following previous SARS-CoV-2 infection (Groups 5 and 6); and ‘SARS-CoV-2 unexposed’ patients (Group 7). Median levels of CRP, GDF-15, IL-6, and sFlt-1 were significantly higher in hospitalized patients with SARS-CoV-2 compared with discharged patients (all p < 0.001), whereas levels of sACE2 were significantly lower (p < 0.001). ROC curve analysis of sACE2 provided cut-offs for predicting hospital admission (≤0.05 ng/mL (positive predictive value: 89.1%) and ≥0.42 ng/mL (negative predictive value: 84.0%)). These findings support further investigation of sACE2, as a single biomarker or as part of a panel, to predict hospitalization risk and disease severity in patients with SARS-CoV-2 infection. MDPI 2022-04-01 /pmc/articles/PMC9031748/ /pubmed/35453934 http://dx.doi.org/10.3390/diagnostics12040886 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Díaz-Troyano, Noelia Gabriel-Medina, Pablo Weber, Stephen Klammer, Martin Barquín-DelPino, Raquel Castillo-Ribelles, Laura Esteban, Angels Hernández-González, Manuel Ferrer-Costa, Roser Pumarola, Tomas Rodríguez-Frías, Francisco Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2 |
title | Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2 |
title_full | Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2 |
title_fullStr | Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2 |
title_full_unstemmed | Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2 |
title_short | Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2 |
title_sort | soluble angiotensin-converting enzyme 2 as a prognostic biomarker for disease progression in patients infected with sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031748/ https://www.ncbi.nlm.nih.gov/pubmed/35453934 http://dx.doi.org/10.3390/diagnostics12040886 |
work_keys_str_mv | AT diaztroyanonoelia solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT gabrielmedinapablo solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT weberstephen solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT klammermartin solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT barquindelpinoraquel solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT castilloribelleslaura solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT estebanangels solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT hernandezgonzalezmanuel solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT ferrercostaroser solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT pumarolatomas solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 AT rodriguezfriasfrancisco solubleangiotensinconvertingenzyme2asaprognosticbiomarkerfordiseaseprogressioninpatientsinfectedwithsarscov2 |